SmartBrief > Health Care > BIO SmartBrief > Pfizer Inc. Profile

Pfizer Inc.

News and overview for Pfizer Inc.

AUDIO from Medialink and Pfizer Inc.: Reduce Holiday Stress to Help Ease Fibromyalgia [Press Release]
PRNewswire | 1 minute ago
AUDIO from Medialink and Pfizer Inc.: Reduce Holiday Stress to Help Ease Fibromyalgia PRNewswire NEW YORK Nov. 23 NEW YORK, Nov. 23 /PRNewswire/ -- Living...


Immunovaccine Licenses Vaccine Platform to Pfizer Animal Health [Press Release]
MarketWire | 7 hours 56 minutes ago
HALIFAX, NOVA SCOTIA -- (Marketwire) -- 11/23/09 -- Immunovaccine Inc. (TSX VENTURE: IMV), a vaccine development company, today announced the signing of an exclusive, worldwide license agreement with Pfizer Animal Health for Immunovaccine's patented vaccine delivery technology. Pfizer Animal Health said it plans to develop enhanced cattle vaccines incorporating Immunovaccine's technology. Under the terms of the agreement, which were not disclosed, Immunovaccine will receive upfront signing f...


Pfizer reportedly to sell generic drugs in Japan - MarketWatch
MarketWatch | 5 days 1 hour 54 minutes ago
The U.S. company's Japanese unit plans to set up a division on Dec. 1 dedicated to drugs whose patents have expired, Japanese business daily Nikkei reported.


FDA Advisory Committee Finds Data Support the Safety and Effectiveness of Prevnar 13 Vaccine for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children [Press Release]
Business Wire | 5 days 3 hours 32 minutes ago
Pfizer Inc (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children. The Company is seeking an indication for active...


Pfizer reports 26% higher profit, but lower sales - MarketWatch
MarketWatch | 34 days 15 hours 36 minutes ago
The world's largest drug maker posted net income of $2.88 billion, or 43 cents a share, compared with $2.28 billion, or 34 cents a share, for the same quarter in 2008.


Merck, Pfizer, J&J lead drug stocks higher - MarketWatch
MarketWatch | 19 days 11 hours 49 minutes ago
Shares of Merck /quotes/comstock/13*!mrk/quotes/nls/mrk (MRK 32.14, +1.47, +4.79%) were up almost 3% to $41.46.


Pfizer subsidiary hit with record fine - MarketWatch
MarketWatch | 37 days 10 hours 20 minutes ago
Pfizer previously agreed to pay an additional $1 billion plus interest to settle civil allegations that it "fraudulently promoted and marketed Bextra, as well as three other drugs in its portfolio, Geodon, an anti-psychotic drug, Zyvox, and antibiotic, and Lyrica, and anti-epileptic drug," the Justice Department said.


Pfizer, Merck may feel pressure from generics - MarketWatch
MarketWatch | 38 days 17 hours 24 minutes ago
This earnings season will also mark the end of an era for the industry titans, as both are in the final phases of major mergers that aimed at refueling their drug pipelines and stoking profits. On Oct. 15, Pfizer is slated to complete its $68 billion takeover of rival Wyeth. Merck is expected to close on its $41 billion acquisition of Schering-Plough Corp. by the end of the quarter.


Pfizer Receives FDA Approval For Geodon (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults [Press Release]
Business Wire | 3 days 9 hours 23 minutes ago
Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.


Pfizer Submits New Pediatric Data For Lipitor (Atorvastatin) To The European Medicines Agency (EMEA) [Press Release]
Business Wire | 5 days 18 hours 41 minutes ago
Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission.


Pfizer gains on results as Biogen Idec retreats - MarketWatch
MarketWatch | 34 days 12 hours 56 minutes ago
Shares of Pfizer /quotes/comstock/13*!pfe/quotes/nls/pfe (PFE 18.20, +0.22, +1.22%) traded up nearly 2% at $18.29.





 1  2  3  4  5  6  7  8  9 ...   Next >

4654 Results

Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more

Company Overview


Company: Pfizer Inc.
Industry: Pharmaceuticals Manufacturers
Website: http://www.pfizer.com

Pfizer pfabricates pfarmaceuticals pfor quite a pfew inpfirmities. The company is the world's largest research-based pharmaceuticals firm. Its best-known products include erectile dysfunction therapy Viagra, pain management drug Celebrex, high-blood-pressure therapy Norvasc, and cholesterol-lowering Lipitor. Pfizer also keeps Fluffy and Fido in mind with its animal health products, including Revolution (antiparasitic). The company markets its pharmaceuticals directly to health care providers and patients; most of its sales are conducted through wholesalers including McKesson and Cardinal Health. Pfizer acquired pharma rival Wyeth in a $68 billion deal in 2009.


Key Numbers

Sales in U.S. Dollars (mil.) 48,296 (2008)
One-year % Growth in Sales -0.3 (2008)
Net Income in U.S. Dollars (mil.) 8,104 (2008)
One-year % Growth in Net Income -0.5 (2008)
Number of Employees 81,800 (2008)
One-year % Growth in Number of Employees -5.5 (2008)
Fiscal Year-End December